Key Takeaways
- Getty Images (GETY) shares skyrocketed over 150% following a landmark display agreement with OpenAI to integrate licensed visual content into ChatGPT.
- AbbVie (ABBV) announced a definitive $10.9 billion cash acquisition of Apogee Therapeutics (APGE), paying a 49% premium to bolster its immunology pipeline.
- Apple (AAPL) CEO Tim Cook warned of "unavoidable" price hikes for devices like the upcoming iPhone 18, citing a "100-year flood" in DRAM and NAND costs driven by AI infrastructure demand.
- China escalated trade tensions by adding MP Materials (MP) and USA Rare Earth (USAR) to its export control list, targeting the "Achilles' heel" of the U.S. critical minerals supply chain.
- REGENXBIO (RGNX) surged 37% in pre-market trading after the U.S. FDA agreed to reverse its rejection of the company’s experimental gene therapy, Navsunli, for Hunter syndrome.
Tech and AI: Strategic Shifts and Supply Shocks
Getty Images (GETY) dominated pre-market headlines, with its stock price more than doubling after announcing a multi-year partnership with OpenAI. The deal will see Getty’s vast library of licensed images displayed within ChatGPT search results, marking a significant pivot for a company that previously led legal challenges against generative AI firms. The market's reaction reflects growing investor confidence in the monetization of high-quality data for AI discovery tools.
Conversely, Apple (AAPL) shares faced pressure as the company grapples with a structural shift in the semiconductor market. CEO Tim Cook described the current shortage of DRAM and NAND memory as a "hundred-year flood," noting that AI hyperscalers and Nvidia (NVDA) are absorbing the vast majority of global supply. Analysts estimate the iPhone 18 Pro could see a price increase of up to $200 as Apple passes these skyrocketing component costs to consumers.
Healthcare M&A and Regulatory Breakthroughs
In the pharmaceutical sector, AbbVie (ABBV) moved aggressively to defend its immunology leadership by acquiring Apogee Therapeutics (APGE) for $135.11 per share. The $10.9 billion deal centers on zumilokibart (APG777), a late-stage antibody for atopic dermatitis that aims to challenge established treatments. AbbVie expects the transaction to close in the third quarter of 2026, further diversifying its portfolio beyond its aging blockbuster, Humira.
REGENXBIO (RGNX) provided a major boost to the biotech sector after the FDA signaled a rare reversal of its previous "Complete Response Letter" for Navsunli. The agency acknowledged that existing clinical data is sufficient for an accelerated approval pathway, removing the requirement for additional untreated control trials. The company plans to resubmit its Biologics License Application (BLA) in Q3 2026, targeting the ultra-rare neurodegenerative Hunter syndrome.
Geopolitical Friction and Global Finance
China’s Ministry of Commerce intensified its trade dispute with the U.S. by placing MP Materials (MP) and USA Rare Earth (USAR) on its export control list. The move prohibits Chinese exporters from supplying dual-use items to these entities, which are central to the U.S. strategy of reducing dependence on Chinese rare earths. While the immediate operational impact may be limited, the designation signals a hardening of Beijing's stance on critical mineral autonomy.
In the semiconductor equipment space, ASML (ASML) denied allegations from U.S. Commerce Secretary Howard Lutnick regarding unauthorized EUV lithography shipments to China. The company maintained that no EUV systems exist in China and that it remains in full compliance with export restrictions. Meanwhile, reports surfaced that the Saudi Central Bank (SAMA) has begun pulling funds from at least two major asset managers, potentially signaling a reallocation of the Kingdom's $520 billion in foreign reserves toward domestic Vision 2030 initiatives.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.